Seeger Weiss LLP Is Investigating The Risk Of Diabetic Ketoacidosis Linked With Use Of Invokana

Aug 26, 2015, 08:00 ET from Seeger Weiss LLP

NEW YORK, Aug. 26, 2015 /PRNewswire/ -- Seeger Weiss LLP reports that in May 2015 the FDA issued a warning about the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin (sold under the brand names Invokana, Farxiga, and Jardiance, respectively), alerting doctors and patients about the risk of Diabetic Ketoacidosis linked to the medications. This class of drugs, called SGLT2 inhibitors, has been approved for use with diet and exercise to lower blood sugar levels in patients with type 2 diabetes. However, the Agency warned that if symptoms of ketoacidosis occur—"difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue or sleepiness"—medical attention should be sought immediately. The FDA is continuing to investigate this serious safety issue.

The FDA approved the first in the new class of diabetes drugs, Janssen Pharmaceuticals' Invokana, on March 29, 2013, and within the first year the drug was linked to 457 reports of adverse events. Many patients who took this drug allege that they were unaware of the potential for diabetic ketoacidosis. Diabetic ketoacidosis occurs when the body begins to use fat stores as an energy source because sugar is unavailable to the cells. This process produces a buildup of ketones in the bloodstream. Ketones are a chemical substance that causes the blood to become acidic, eventually leading to diabetic ketoacidosis. In patients which this occurs, hospitalization is required and the condition can be potentially fatal.

Seeger Weiss LLP is currently investigating Invokana. If you believe you have been injured due to taking Invokana or wish to learn more, go to our Invokana Lawsuit page.

Seeger Weiss LLP is one of the nation's leading trial law firms handling complex individual, mass and class action litigation on behalf of consumers, investors, injured persons and whistleblowers. The firm, with offices in New York, Philadelphia and New Jersey, represents plaintiffs throughout litigation and as trial counsel in a variety of practice areas, including financial, securities and investment fraud, pharmaceutical injury, consumer protection, qui tam (whistleblower cases), environmental and asbestos exposures, personal injury and medical malpractice, product defect, antitrust, and commercial disputes. For more information, go to www.seegerweiss.com.

http://www.fda.gov/drugs/drugsafety/ucm446845.htm

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm

http://www.ismp.org/quarterwatch/pdfs/2014Q2.pdf

http://www.mayoclinic.org/diseases-conditions/diabetic-ketoacidosis/basics/definition/con-20026470

Contact: 
Christopher A. Seeger, (212) 584-0700 or cseeger@seegerweiss.com 
Jeffrey S. Grand (212) 584-0700 or jgrand@seegerweiss.com 

Logo - http://photos.prnewswire.com/prnh/20150527/218876LOGO

SOURCE Seeger Weiss LLP



RELATED LINKS

http://www.seegerweiss.com